DESIPRAMINE

地昔帕明

• 批准号: 2240641
• 负责人: Thomas J Spencer
• 金额: $ 14.01万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-05-01 至 1999-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2240641
• 关键词: Tourette's syndrome; abnormal involuntary movement; academic achievement; adolescence (12-20); anxiety; attention deficit disorder; behavior test; blood chemistry; child behavior; clinical trials; depression; desipramine; drug screening /evaluation; human subject; human therapy evaluation; intelligence tests; mental disorder chemotherapy; mental disorder diagnosis; middle childhood (6-11); neuropsychological tests; pediatric pharmacology; pharmacokinetics; psychopharmacology; sign /symptom; tricyclic antidepressant

In order to address a compelling public health concern and to gain mentored research experience, the candidate proposes to double-blind, controlled, study of dispramine (DMI) treatment in children and adolescents with ADHD and Tics Disorders or Tourettes.

为了解决紧迫的公共卫生问题并获得 指导研究经验，候选人建议双盲， 儿童和儿童迪帕明 (DMI) 治疗的对照研究 患有多动症和抽动症或抽动秽语症的青少年。